A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2014
At a glance
- Drugs DBPR 108 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01650324).
- 27 Jul 2012 Official title amended, planned number of patients 54 added and additional lead trial centre identified as reported by ClinicalTrials.gov.